2009年至2011年医院乳腺癌内分泌治疗药物应用分析  

Application Analysis of Endocrine Therapeutic Drugs for Breast Cancer in Our Hospital during 2009 — 2011

作　　者：单文治[1] 裴保香[1] 木阿龙 

机构地区：[1]中国人民解放军总医院药品保障中心,北京100853

出　　处：《中国药业》2014年第21期74-76,共3页China Pharmaceuticals

摘　　要：目的了解医院乳腺癌内分泌治疗药物的临床应用情况及发展趋势。方法对医院2009年至2011年乳腺癌内分泌治疗药物的年度消耗量、年度用药金额、用药频度(DDDs)及限定日费用(DDDc)等指标进行统计分析。结果内分泌治疗药物的年度用药金额总量缓慢增长,促皮质素类与抗孕激素类基本持平,孕激素类小幅下降;年度总DDDs也缓慢增长,其中芳香酶抑制剂类药物增幅最大,阿那曲唑的年度增长率达20%以上,其他药物呈不同幅度下降。DDDs排序由高到低前3位的是他莫昔芬、阿那曲唑、来曲唑。结论使用最多的药物仍是他莫昔芬,第3代芳香酶抑制剂类药物越来越受欢迎,阿那曲唑更是为临床医师所青睐。Objective To understand the clinical application situation and development tendency of endocrine therapeutic drugs for breast cancer in our hospital. Methods The annual consumption quantity,annual consumption sum,annual DDDs and DDDc of endocrine therapeutic drugs for breast cancer in our hospital during the period 2009 — 2011 were analyzed statistically. Results The consumption sum of endocrine therapeutic drugs in our hospital was increased slowly year by year; corticotrophins and antiprogestogen drugs were basically flat, progesterones were dropped in small quantity; the annual consumption sum of drugs also showed the slowly increasing trend, in which Aromatase inhibitors had the maximal amplification,the annual increasing rate of anastrozole reached over 20%. The other drugs showed the different amplitudes of decrease. The ranking in DDDs were in turn tamoxifen, anatrozole and letrozole. Conclusion The most commonly used medicine is still tamoxifen,the third generation aromatase inhibitors get more popular,anatrozole is favorite by the clinical doctors.

关 键 词：乳腺癌 内分泌治疗 用药分析 金额 用药频度 

分 类 号：R969.3[医药卫生—药理学] R977.12[医药卫生—药学]